Anna Richo
Known title: DirectorCIK: 0001199306
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Exelon Faces Lowered Target Amid Battery Storage Focus. Truist Securities kept a hold stance on Exelon but cut its price target to $46, reflecting concerns about the company's battery storage plans and the shift in the grid driven by data center demand. The company’s battery storage push has brought its fair value back into focus, while the data center power boom could reshape its revenue mix. Exelon’s current price sits near its support level of $45.41, and the RSI suggests it is not yet oversold.
Transaction History
| ILMN | ▲ Buy | Grant | 2,072 | $300K | 5/21/2026 | View on chart |
| EXC | ▲ Buy | Grant | 878 | $44K | 3/31/2026 | View on chart |
| EXC | ▲ Buy | Grant | 940 | $41K | 12/31/2025 | View on chart |
| EXC | ▲ Buy | Grant | 950 | $41K | 9/30/2025 | View on chart |
| EXC | ▲ Buy | Grant | 954 | $41K | 6/30/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 3,780 | $0 | 5/21/2025 | View on chart |
| EXC | ▲ Buy | Grant | 933 | $41K | 3/31/2025 | View on chart |
| EXC | ▲ Buy | Grant | 1,119 | $41K | 12/31/2024 | View on chart |
| EXC | ▲ Buy | Grant | 1,025 | $41K | 9/30/2024 | View on chart |
| EXC | ▲ Buy | Grant | 1,161 | $41K | 6/30/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 2,622 | $0 | 5/16/2024 | View on chart |
| EXC | ▲ Buy | Grant | 1,131 | $41K | 3/31/2024 | View on chart |
| EXC | ▲ Buy | Grant | 1,052 | $41K | 12/31/2023 | View on chart |
| EXC | ▲ Buy | Grant | 674 | $27K | 9/30/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.